UBS Group
ACHN

UBS Group’s Achillion Pharmaceuticals ACHN Stock Holding History

UBS Group’s Portfolio ACHN Stock Details ACHN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-1,300
Closed -$14K – 8463
2015
Q4 		$14K Hold
1,300
– – ﹤0.01% 7098
2015
Q3 		$9K Hold
1,300
– – ﹤0.01% 7363
2015
Q2 		$12K Hold
1,300
– – ﹤0.01% 7349
2015
Q1 		$13K Sell
1,300
-155,000
-99% -$1.94M ﹤0.01% 7453
2014
Q4 		$1.92M Buy
+156,300
New +$1.91M ﹤0.01% 2948

UBS Group's ACHN Position: Q1 2020 in Review

UBS Group sold out of Achillion Pharmaceuticals (ACHN) in Q1 2020, closing a stake of 3,869,063 shares — an estimated $23.3M sold.

UBS Group first reported a position in ACHN in Q4 2014 and held it in 21 quarters. The position peaked at $23.3M in Q4 2019. 0 funds tracked by Wall St. Rank hold ACHN as of Q1 2020.

  • UBS Group reported no remaining Achillion Pharmaceuticals position as of Q1 2020 after selling out during the quarter.
  • UBS Group sold 3,869,063 Achillion Pharmaceuticals shares in Q1 2020, an estimated $23.3M.
  • UBS Group first reported a position in Achillion Pharmaceuticals in Q4 2014 and held it in 21 quarters.
  • UBS Group's Achillion Pharmaceuticals position peaked at $23.3M in Q4 2019.
  • 0 funds tracked by Wall St. Rank held Achillion Pharmaceuticals as of Q1 2020.

Based on UBS Group's 13F filing for Q1 2020, filed 1 May 2020.